source
- Biotech reverse mergers surge 1,600% in Q3, matching number of IPOs in 2026Biotech companies are turning to reverse mergers as a faster, less volatile route to the public markets. In the third quarter of 2026, 17 reverse mergers were completed or announced, a 1,600% incre…
- Alumis' TYK2 inhibitor flunks mid-stage lupus trial, shares drop 55%Alumis reported that its experimental TYK2 inhibitor, envudeucitinib, failed to meet any primary or secondary endpoints in a mid-stage study of systemic lupus erythematosus. The company highlighte…